Locations:
Search IconSearch
July 13, 2021/Cancer

New AUA Guideline Focuses on Approach to Localized Renal Masses and Cancers

AUA review consolidates and updates two earlier documents into one evidence-based document

3D animation stills

A new guideline from the American Urological Association provides clinicians with advice on best practices for managing patients with localized renal masses and cancers.The document is an update of two earlier guidelines, providing key evidence on evaluation and management of localized kidney cancer and surveillance after treatment, now merged into a single publication.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Developed under the leadership of experts from Cleveland Clinic and other leading kidney cancer centers, “Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-up” takes a fresh look at such clinically important issues as:

  • Expanded indications for genetic counseling.
  • Adjuvant therapy for patients at high risk of recurrence.
  • Use of magnetic resonance imaging (MRI) with contrast in patients with severe chronic kidney disease (CKD) or end-stage renal disease (ESRD).
  • Indications and rationale for active surveillance of patients with renal lesions.
  • Follow-up of patients on active surveillance.
  • Indications for renal mass biopsy (RMB).

How the guidelines were developed

“The new guidelines are based on a robust systematic review of the literature bringing all up to date as of late 2020,” says Steven C. Campbell, MD, PhD, chair of the AUA Renal Mass Guideline Panel and Vice Chairman of Urology at Cleveland Clinic. “This document provides clinicians with everything they need to know to take an evidence-based approach to evaluation and management of patients with localized kidney cancer and renal masses.”

To identify the literature to be reviewed, the panel used the same key questions and search criteria as for the Renal Mass and Localized Renal Cancer guidelines published in 2013 and 2017. The result was a “deep dive” into evidence in that area, spanning from January 1, 1997, through October 2020, and the capture of several additional studies.

In the process the panel merged the Renal Mass and Localized Renal Cancer guideline with a separate guideline on Follow-Up for Clinically Localized Renal Neoplasms.

Advertisement

Strength of evidence ratings—grades A for high, B for moderate, and C for low—were assigned to the body of evidence for a particular treatment when the panel found that sufficient evidence existed in the literature. In the absence of sufficient evidence, the guideline provides additional information, in the form of Clinical Principles and Expert Opinions.

Recommendations

The guideline includes 45 statements: 13 on initial evaluation and diagnosis, 19 on management, and 13 on follow-up after intervention. “None of the changes are earth-shattering, but they are all important and clinically relevant,” says Dr. Campbell. “In most cases, we fine-tuned the statements and provided more granular and clinically useful information.”

One example is the statement on radical nephrectomy (RN), which includes specific criteria for performing the procedure in patients with a solid or Bosniak 3/4 complex cystic renal mass whenever increased oncologic potential is suggested by tumor size, RMB (if obtained), and/or imaging features suggesting infiltrative or locally advanced features. In this setting RN is preferable if all of the following criteria are met: (1) the tumor is high complexity and partial nephrectomy would be challenging even in experienced hands; (2) the patient does not have preexisting CKD or proteinuria; and (3) the patient has a normal contralateral kidney and the new baseline estimated glomerular filtration rate (eGFR) will likely be >45 mL/min/1.73m2 even if RN is performed. The panel also notes that PN should be considered if all of these conditions are not met, unless there are overriding concerns about the safety or oncologic efficacy of PN.

Advertisement

“Which patients should get RN has been a very controversial issue and European and NCCN guidelines leave it up to the surgeon to decide just based on whether PN is thought to be feasible,” says Dr. Campbell. “The AUA guidelines are the only ones that provide granular and concrete information to help clinicians make solid decisions about this important issue.”

Among the other updates of particular note to clinicians are recommendations for active surveillance and expert advice on the role of contrast-enhanced MRI. “The 2017 guidelines indicated that contrast-enhanced MRI was inappropriate for patients with severe CKD and a GFR < 30mL/min/1.73m2,” says Dr. Campbell, “but with newer group II and III gadolinium-based contrast media, the risk is lower and it is safe, and the guidelines’ recommendations were changed to acknowledge this.”

What is most important for clinicians to know about the guidelines is that they are just that: guidelines. “At Cleveland Clinic, we do a pretty good job of following the main tenets, and we treat as many or more patients with kidney cancer than just about any other hospital in the world,” says Dr. Campbell. “But the reality is that it’s not 100% adherence. These are general recommendations that need to be interpreted within the context of the patient in front of you, with all the complexities that individual presents.”

Advertisement

Related Articles

Cancer researchers
December 5, 2024/Cancer/News & Insight
Study Examines Neoantigen Landscapes and Their Role in Immunotherapy Efficacy

Researchers develop first-of-its-kind neoantigen atlas to better understand immunotherapy resistance

Interactive culinary medicine class
November 11, 2024/Cancer/Innovations
Integrative Oncology Improves Outcomes and Quality of Life

Combining mind, body and lifestyle practices in alignment with conventional cancer treatment

Pregnant woman
November 6, 2024/Cancer/News & Insight
Large Retrospective Study Finds Pregnancy Safe Among Young BRCA Carriers

Pregnancy did not appear to increase the risk of recurrence in patients or complications in their children

Young patient with cancer
October 25, 2024/Cancer/News & Insight
Multidisciplinary Care Model Supports Young People with Cancer

Integrated program addresses growing need for comprehensive cancer care among adolescents, young adults and adults under 50 with early onset cancers

Hurthle cell carcinoma
October 24, 2024/Cancer/News & Insight
Researchers Uncover Clues to Treating Rare Thyroid Cancer

Studies find mTOR inhibitor may play key role in treating Hurthle cell carcinoma

DNA
October 10, 2024/Cancer/Research
Blocking YES1 Protein Resensitizes Triple-Negative Breast Cancer to Treatment

Obstructing key protein allows for increased treatment uptake for taxane chemotherapy

Ad